Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
102.2 EUR | +0.69% | +1.49% | +1.59% |
Apr. 26 | BioMérieux: share price rises, analyst remains Buy | CF |
Apr. 26 | BIOMÉRIEUX : Berenberg raises its target | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- With a 2024 P/E ratio at 26.11 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.59% | 12.8B | B+ | ||
-10.29% | 7.61B | B- | ||
+3.13% | 5.41B | B | ||
-1.16% | 4.51B | C | ||
+7.71% | 4.49B | C | ||
+12.21% | 2.73B | - | - | |
-15.15% | 2.02B | B- | ||
-11.50% | 1.73B | D+ | ||
-0.68% | 1.64B | C | ||
-8.80% | 1.53B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BIM Stock
- Ratings bioMérieux